Long-term clinical outcomes after sirolimus-eluting stent implantation for treatment of restenosis within bare-metal versus drug-eluting stents

Whan Lee Cheol, Sang Hyun Kim, Jon Suh, Duk Woo Park, Seung Hwan Lee, Young Hak Kim, Myeongki Hong, Jae Joong Kim, Seong Wook Park, Seung Jung Park

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background: Sirolimus-eluting stents have been increasingly used for treatment of restenosis after implantation of bare metal stents (BMSs) or drug-eluting stents (DESs), but little is known regarding their long-term outcomes. Methods: We compared long-term clinical outcomes in 295 patients treated with sirolimus-eluting stents for post-BMS (n = 224) vs. post-DES (n = 71) restenosis. All follow-ups were at least 12 months, and the primary endpoint was major adverse cardiac events (MACE), defined as cardiac death, nonfatal myocardial infarction (MI) or target lesion revascularization (TLR). Results: Baseline characteristics were similar between the two groups, except that mean lesion length (28.0 ± 16.2 vs. 19.5 ± 13.6, P < 0.01) and mean stented length (35.4 ± 19.2 vs. 25.7 ± 14.7, P < 0.01) were significantly longer in the post-BMS group. Major in-hospital complications occurred in 2 patients. During a mean follow-up of 31.3 ± 11.1 months, there were 9 deaths (4 cardiac, 5 noncardiac), 3 nonfatal MIs, and 25 TLRs. Late stent thrombosis was documented in 2 patients (1 in each group). There were no between group differences in cardiac or total deaths, but there were trends toward less frequent cardiac death/MI or TLR in the post-BMS group. The cumulative probability of MACE-free survival was significantly better for the post-BMS group (95.0% ± 1.5% vs. 87.3% ± 4.0% at 1 year; 93.0% ± 1.7% vs. 81.0% ± 5.2% at 2 years; Log Rank P = 0.016). In multivariate analysis, post-DES restenosis was the only significant predictor of MACE (OR 3.29, 95%CI 1.13-9.61, P = 0.029). Conclusions: Sirolimus-eluting stents were effective for treatment of in-stent restenosis, but post-DES restenosis was associated with poorer outcomes than post-BMS restenosis.

Original languageEnglish
Pages (from-to)594-598
Number of pages5
JournalCatheterization and Cardiovascular Interventions
Volume71
Issue number5
DOIs
Publication statusPublished - 2008 Apr 1

Fingerprint

Drug-Eluting Stents
Sirolimus
Stents
Metals
Therapeutics
Myocardial Infarction
Disease-Free Survival
Thrombosis
Multivariate Analysis

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

Cheol, Whan Lee ; Kim, Sang Hyun ; Suh, Jon ; Park, Duk Woo ; Lee, Seung Hwan ; Kim, Young Hak ; Hong, Myeongki ; Kim, Jae Joong ; Park, Seong Wook ; Park, Seung Jung. / Long-term clinical outcomes after sirolimus-eluting stent implantation for treatment of restenosis within bare-metal versus drug-eluting stents. In: Catheterization and Cardiovascular Interventions. 2008 ; Vol. 71, No. 5. pp. 594-598.
@article{704d197a8deb49e288e3eee5d1d3b9fd,
title = "Long-term clinical outcomes after sirolimus-eluting stent implantation for treatment of restenosis within bare-metal versus drug-eluting stents",
abstract = "Background: Sirolimus-eluting stents have been increasingly used for treatment of restenosis after implantation of bare metal stents (BMSs) or drug-eluting stents (DESs), but little is known regarding their long-term outcomes. Methods: We compared long-term clinical outcomes in 295 patients treated with sirolimus-eluting stents for post-BMS (n = 224) vs. post-DES (n = 71) restenosis. All follow-ups were at least 12 months, and the primary endpoint was major adverse cardiac events (MACE), defined as cardiac death, nonfatal myocardial infarction (MI) or target lesion revascularization (TLR). Results: Baseline characteristics were similar between the two groups, except that mean lesion length (28.0 ± 16.2 vs. 19.5 ± 13.6, P < 0.01) and mean stented length (35.4 ± 19.2 vs. 25.7 ± 14.7, P < 0.01) were significantly longer in the post-BMS group. Major in-hospital complications occurred in 2 patients. During a mean follow-up of 31.3 ± 11.1 months, there were 9 deaths (4 cardiac, 5 noncardiac), 3 nonfatal MIs, and 25 TLRs. Late stent thrombosis was documented in 2 patients (1 in each group). There were no between group differences in cardiac or total deaths, but there were trends toward less frequent cardiac death/MI or TLR in the post-BMS group. The cumulative probability of MACE-free survival was significantly better for the post-BMS group (95.0{\%} ± 1.5{\%} vs. 87.3{\%} ± 4.0{\%} at 1 year; 93.0{\%} ± 1.7{\%} vs. 81.0{\%} ± 5.2{\%} at 2 years; Log Rank P = 0.016). In multivariate analysis, post-DES restenosis was the only significant predictor of MACE (OR 3.29, 95{\%}CI 1.13-9.61, P = 0.029). Conclusions: Sirolimus-eluting stents were effective for treatment of in-stent restenosis, but post-DES restenosis was associated with poorer outcomes than post-BMS restenosis.",
author = "Cheol, {Whan Lee} and Kim, {Sang Hyun} and Jon Suh and Park, {Duk Woo} and Lee, {Seung Hwan} and Kim, {Young Hak} and Myeongki Hong and Kim, {Jae Joong} and Park, {Seong Wook} and Park, {Seung Jung}",
year = "2008",
month = "4",
day = "1",
doi = "10.1002/ccd.21399",
language = "English",
volume = "71",
pages = "594--598",
journal = "Catheterization and Cardiovascular Interventions",
issn = "1522-1946",
publisher = "Wiley-Liss Inc.",
number = "5",

}

Long-term clinical outcomes after sirolimus-eluting stent implantation for treatment of restenosis within bare-metal versus drug-eluting stents. / Cheol, Whan Lee; Kim, Sang Hyun; Suh, Jon; Park, Duk Woo; Lee, Seung Hwan; Kim, Young Hak; Hong, Myeongki; Kim, Jae Joong; Park, Seong Wook; Park, Seung Jung.

In: Catheterization and Cardiovascular Interventions, Vol. 71, No. 5, 01.04.2008, p. 594-598.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Long-term clinical outcomes after sirolimus-eluting stent implantation for treatment of restenosis within bare-metal versus drug-eluting stents

AU - Cheol, Whan Lee

AU - Kim, Sang Hyun

AU - Suh, Jon

AU - Park, Duk Woo

AU - Lee, Seung Hwan

AU - Kim, Young Hak

AU - Hong, Myeongki

AU - Kim, Jae Joong

AU - Park, Seong Wook

AU - Park, Seung Jung

PY - 2008/4/1

Y1 - 2008/4/1

N2 - Background: Sirolimus-eluting stents have been increasingly used for treatment of restenosis after implantation of bare metal stents (BMSs) or drug-eluting stents (DESs), but little is known regarding their long-term outcomes. Methods: We compared long-term clinical outcomes in 295 patients treated with sirolimus-eluting stents for post-BMS (n = 224) vs. post-DES (n = 71) restenosis. All follow-ups were at least 12 months, and the primary endpoint was major adverse cardiac events (MACE), defined as cardiac death, nonfatal myocardial infarction (MI) or target lesion revascularization (TLR). Results: Baseline characteristics were similar between the two groups, except that mean lesion length (28.0 ± 16.2 vs. 19.5 ± 13.6, P < 0.01) and mean stented length (35.4 ± 19.2 vs. 25.7 ± 14.7, P < 0.01) were significantly longer in the post-BMS group. Major in-hospital complications occurred in 2 patients. During a mean follow-up of 31.3 ± 11.1 months, there were 9 deaths (4 cardiac, 5 noncardiac), 3 nonfatal MIs, and 25 TLRs. Late stent thrombosis was documented in 2 patients (1 in each group). There were no between group differences in cardiac or total deaths, but there were trends toward less frequent cardiac death/MI or TLR in the post-BMS group. The cumulative probability of MACE-free survival was significantly better for the post-BMS group (95.0% ± 1.5% vs. 87.3% ± 4.0% at 1 year; 93.0% ± 1.7% vs. 81.0% ± 5.2% at 2 years; Log Rank P = 0.016). In multivariate analysis, post-DES restenosis was the only significant predictor of MACE (OR 3.29, 95%CI 1.13-9.61, P = 0.029). Conclusions: Sirolimus-eluting stents were effective for treatment of in-stent restenosis, but post-DES restenosis was associated with poorer outcomes than post-BMS restenosis.

AB - Background: Sirolimus-eluting stents have been increasingly used for treatment of restenosis after implantation of bare metal stents (BMSs) or drug-eluting stents (DESs), but little is known regarding their long-term outcomes. Methods: We compared long-term clinical outcomes in 295 patients treated with sirolimus-eluting stents for post-BMS (n = 224) vs. post-DES (n = 71) restenosis. All follow-ups were at least 12 months, and the primary endpoint was major adverse cardiac events (MACE), defined as cardiac death, nonfatal myocardial infarction (MI) or target lesion revascularization (TLR). Results: Baseline characteristics were similar between the two groups, except that mean lesion length (28.0 ± 16.2 vs. 19.5 ± 13.6, P < 0.01) and mean stented length (35.4 ± 19.2 vs. 25.7 ± 14.7, P < 0.01) were significantly longer in the post-BMS group. Major in-hospital complications occurred in 2 patients. During a mean follow-up of 31.3 ± 11.1 months, there were 9 deaths (4 cardiac, 5 noncardiac), 3 nonfatal MIs, and 25 TLRs. Late stent thrombosis was documented in 2 patients (1 in each group). There were no between group differences in cardiac or total deaths, but there were trends toward less frequent cardiac death/MI or TLR in the post-BMS group. The cumulative probability of MACE-free survival was significantly better for the post-BMS group (95.0% ± 1.5% vs. 87.3% ± 4.0% at 1 year; 93.0% ± 1.7% vs. 81.0% ± 5.2% at 2 years; Log Rank P = 0.016). In multivariate analysis, post-DES restenosis was the only significant predictor of MACE (OR 3.29, 95%CI 1.13-9.61, P = 0.029). Conclusions: Sirolimus-eluting stents were effective for treatment of in-stent restenosis, but post-DES restenosis was associated with poorer outcomes than post-BMS restenosis.

UR - http://www.scopus.com/inward/record.url?scp=42249113032&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42249113032&partnerID=8YFLogxK

U2 - 10.1002/ccd.21399

DO - 10.1002/ccd.21399

M3 - Article

C2 - 18311841

AN - SCOPUS:42249113032

VL - 71

SP - 594

EP - 598

JO - Catheterization and Cardiovascular Interventions

JF - Catheterization and Cardiovascular Interventions

SN - 1522-1946

IS - 5

ER -